# A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae

> **NCT07647029** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 126 (estimated)

## Conditions studied

- Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)

## Interventions

- **DRUG:** Continuous Hetrombopag for 2 Cycles
- **DRUG:** Cyclic 14-day Hetrombopag for 2 Cycles

## Key facts

- **NCT ID:** NCT07647029
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-28
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-03-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647029, "A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*